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Abstract
In smoking cessation clinical trials, subjects commonly experience a series of lapse and recovery episodes of
varying lengths. Any quit episode may become permanent, in the sense that the subject stops smoking for
good, and any lapse may also become permanent, in the sense that the subject abandons the quit attempt
entirely. Individual quit patterns may reflect the effects of treatment and measured and unmeasured covariates.
To describe this complex data structure, we propose a multivariate time-to-event model that i) incorporates
alternating recurrent events of two types, each with the possibility of "cure", ii) allows for the modifying
effects of treatment and covariates, and iii) reflects within-subject correlation via frailties. Specifically, we
introduce a novel cure-mixture frailty model in which the cure probability follows a binary regression and the
time to event given not cured is determined by a proportional hazard model. We then extend it to data with
recurring events of two alternating types, where we assume that each type of event has a gamma frailty, and we
link the frailties by means of a Clayton copula. In my first project, I fit this model to data from a smoking
cessation drug trial. In my second project, I developed a Bayesian method to predict individual long-term
smoking behavior from observed short-term quit/relapse patterns. In my third project, I investigated the
theoretical properties of the survival distribution, evidently not previously described, that arises from our
cure-mixture frailty model.
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ABSTRACT
STATISTICAL MODELING OF DATA FROM SMOKING CESSATION CLINICAL TRIALS
Yimei Li
Daniel F. Heitjan
In smoking cessation clinical trials, subjects commonly experience a series of lapse
and recovery episodes of varying lengths. Any quit episode may become permanent,
in the sense that the subject stops smoking for good, and any lapse may also become
permanent, in the sense that the subject abandons the quit attempt entirely. Individ-
ual quit patterns may reflect the effects of treatment and measured and unmeasured
covariates.
To describe this complex data structure, we propose a multivariate time-to-event
model that i) incorporates alternating recurrent events of two types, each with the
possibility of ”cure”, ii) allows for the modifying effects of treatment and covariates,
and iii) reflects within-subject correlation via frailties. Specifically, we introduce
a novel cure-mixture frailty model in which the cure probability follows a binary
regression and the time to event given not cured is determined by a proportional
hazard model. We then extend it to data with recurring events of two alternating
types, where we assume that each type of event has a gamma frailty, and we link the
frailties by means of a Clayton copula. In my first project, I fit this model to data
from a smoking cessation drug trial. In my second project, I developed a Bayesian
method to predict individual long-term smoking behavior from observed short-term
quit/relapse patterns. In my third project, I investigated the theoretical properties
iii
of the survival distribution, evidently not previously described, that arises from our
cure-mixture frailty model.
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Chapter 1
Introduction
In a typical smoking cessation trial, each patient designates a target quit date
(TQD). Counseling and/or drug treatment begin prior to the TQD, and treatment
may run for eight or more weeks post-TQD, with follow-up data gathered at intervals
during treatment and at the end of treatment (EOT). The traditional primary out-
come variable is a measure of abstinence at EOT, which we code as a binary variable
and analyze using well-established methods such as logistic regression. Alternatively,
some trials use the length of the period of abstinence prior to the initial failure, which
we would then analyze using univariate time-to-event models.
However, these approaches are potentially inefficient in that they ignore the wealth
of behavioral information in the raw daily smoking records. Commonly, a quit at-
tempt consists of a series of setbacks and recoveries, potentially culminating in success.
This unique feature poses challenging methodological problems on statistical model-
ing. For instance, the multiple transitions between smoking and abstinence induce
two critical endpoints, time to lapse and time to recovery, and one need to model such
1
pair of recurrent events jointly. Moreover, the possibility of permanence of an episode
needs to be incorporated into the analysis, which the traditional time-to-event model
cannot handle.
Therefore, the first aim of this dissertation is to develop statistical methods to
describe the complex data structure arising from smoking cessation clinical trials.
In Chapter 2, we propose a flexible parametric model to describe alternating-states
recurrent-event data where there is a possibility of cure with each type of event. We
begin by introducing a novel cure-mixture frailty model in which a common frailty
influences both the cure probability and the hazard function given not cured. We
then extend our model to data with recurring events of two alternating types. We
assume that each type of event has a gamma frailty, and we link the frailties by a
Clayton copula. We illustrate the model with an analysis of data from two smoking
cessation trials comparing bupropion and placebo. We also conduct simulation studies
to demonstrate that our method performs well in repeated samples of practical size.
Another interesting characteristic about smoking cessation trials is that although
the outcome at the end of this period is an important indicator of treatment success,
substantial uncertainty remains on how an individual’s smoking behavior will evolve
over time. It is of great interest to predict subjects’ further outcomes, because this
will help researchers to optimize the intervention to meet the smoking cessation needs
of different individuals. Therefore as the second aim of this dissertation, we develop
a method to predict individual long-term smoking cessation success based on his/her
short-term clinical observations. In Chapter 3, we describe such a Bayesian method
for prediction, based on our cure-mixed frailty model proposed in Chapter 2. More
2
specifically, it’s a two-stage prediction algorithm that first uses importance sampling
to generate subject-specific frailties from their posterior distributions conditional on
the observed data, then samples predicted future smoking behavior trajectories from
the estimated model parameters and sampled frailties. We apply the method to the
same smoking cessation data as in Chapter 2. The results suggest that the predictions
from our method are better than those from a variety of empirical prediction methods.
In Chapter 4, we divert from smoking cessation trials to some theoretical deriva-
tions about a new survival distribution we discovered during the work in Chapter
2. We denote it as the Complementary Mixture Pareto II distribution (CMPII)
and describe its properties in detail. We demonstrate its connections with existing
distributions including the Pareto and exponential. We also derive its expectation,
variance, characteristic function and moments.
3
Chapter 2
A Multivariate Cure-Mixture
Frailty Model for Smoking
Cessation Data
2.1 Introduction
Subjects in smoking cessation trials commonly transit several times between lapse
and recovery. An important feature of such data is that any quit episode may become
permanent, in the sense that the subject stops smoking for good, and any lapse may
also become permanent, in the sense that the subject abandons the quit attempt
entirely. The notion that subjects exhibit both temporary and permanent quits is
well established in smoking cessation research (USDHHS (1990)) and has found sup-
port in recent statistical analyses of smoking cessation data sets (Cook et al. (2002);
Mannan and Koval (2003); Banerjee and Carlin (2004); Yu and Peng (2008); Luo et
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al. (2008)). Another important aspect of such data is that an individual’s quit pat-
tern may reflect underlying factors that are not readily encoded in covariates. This
manifests itself as correlation between repeated outcomes, such as series of quit and
lapse durations within individuals. Thus a comprehensive model for a smoking cessa-
tion data set would also need to include the possibility of correlation between events
within individuals. We consider these elements — recurrent events, cure modeling,
and modeling of correlation — in turn below.
Recurrent events. Recurrent-event data arise when subjects can have repeated
episodes of the event in question; common examples in medicine include coronary
infarctions, relapses of cancer, and loss of viral control in HIV infection. Most analy-
ses of multiple failure times have used extended versions of the Cox model, although
the same extensions apply to parametric models. Unlike their single-event counter-
parts, there are many structural choices to make in describing the time origin and
at-risk status for an individual episode (Hosmer and Lemeshow (1999); Kelly and
Lim (2000)). In smoking cessation studies, the appropriate modeling strategy is one
in which the subject returns to the risk set only at the end of the preceding event
(Andersen et al. (1993); Therneau and Hamilton (1997)).
Cure models. In survival analysis we typically assume that all subjects are gen-
uinely at risk and will eventually experience an event. In some applications, however,
a fraction may either be or become nonsusceptible. An example is time to recurrence
of cancer among patients treated with surgery, where we may find that some patients
never recur, presumably because the operation removed every vestige of the tumor
(Withers et al. (1995)). Cure models were devised to describe such data. The perti-
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nent literature begins with Farewell (1983), who used logistic regression to model the
cured fraction and Weibull regression to model the non-cured event rate. Kuk and
Chen (1992) proposed a Cox model for non-cured survival, and Peng et al. (1998)
modeled the survival component with a generalized F . Attempts to model such data
semiparametrically encounter vexing identifiability problems, because nonparamet-
ric survival estimates need not decline to zero (Peng and Carriere (2002)). Sy and
Taylor (2000) therefore proposed a proportional hazards model with a zero-tail con-
straint, and Li and Taylor (2002) described non-cured survival with a semiparametric
accelerated failure time model, which handles identifiability more gracefully.
Modeling heterogeneity/correlation. A popular device for extending the classical
survival model to account for between-unit heterogeneity (within-unit correlation)
is the frailty model, first proposed by Vaupel et al. (1979). A typical frailty model
assumes that all subjects’ survival distributions follow a common form up to a ran-
dom subject-specific effect, known as a frailty. One then integrates out this latent
factor to derive a new marginal distribution for the data. The introduction of frail-
ties can describe lack of fit to classical survival models, between-subject heterogene-
ity, and within-subject correlation in clustered, multivariate or recurrent outcomes.
Practitioners commonly assume that frailties follow a distribution from the power
variance function family, such as the gamma, inverse Gaussian, or positive stable law
(Hougaard (1986, 1994)).
Several authors have proposed extending the basic frailty model to incorporate
the possibility of cure. Aalen (1988) included distributions with a nonsusceptible
subgroup and developed these models further using a class of compound Poisson
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distributions (Aalen (1992)). Longini and Halloran (1996) proposed frailty mixture
models, and Price and Manatunga (2001) elaborated the idea of applying the frailty
concept to cure models. Chen et al. (1999, 2002) andYin and Ibrahim (2005) described
models for cancer recurrence in which a latent Poisson variable gives the number of
surviving malignant clones in a treated subject, with the subject’s overall time to
recurrence being the minimum of the times to clinical observability generated by the
clones; a subject with zero clones is cured.
In this chapter we propose a model to describe data on series of lapse and recovery
episodes from subjects participating in a smoking cessation trial. In §2.2, we introduce
a frailty model with cure fraction, its extensions, and estimation methods. In §2.3,
we apply the proposed model to a smoking cessation data set. In §2.4 we present
simulation results, and we offer concluding comments in §2.5.
2.2 Statistical Models
2.2.1 A Cure-Mixture Frailty Model
First consider univariate time-to-event data. We let Ti and Si(ti) denote a single
event time with its survival function for subject i, and assume that the subject is either
cured (with probability pii) or has a proper survival function S
∗
i (ti) (with probability
1− pii):
Si(ti) = pii + (1− pii)S∗i (ti). (2.2.1)
7
To account for heterogeneity, we assume that each subject has an unknown, latent
frailty, denoted bi, that affects both the cure fraction and the survival hazard. We
further assume that, conditional on bi, the cure probability follows a binary regression
with a complementary log-log (cloglog) link, and time to event given not cured is
determined by a proportional hazard model with a constant baseline hazard. Thus,
pii(bi) = exp[−bi exp(−ηpii)], S∗i (ti|bi) = exp[−tibi exp(ησi)], (2.2.2)
where ηpii and ησi are linear predictors for the cure fraction and event rate, respectively.
We represent the linear predictors as
ηpii = αpi + βpiVi, ησi = ασ + βσWi , (2.2.3)
where the predictor vectors Vi andWi may overlap. Letting h
∗
i be the hazard function
associated with S∗i , we can rewrite Equations (2.2.1) and (2.2.2) as
ln(− ln pii(bi)) = ln bi + αpi + βpiVi, lnh∗i (ti| bi) = ln bi + ασ + βσWi.
In our parameterization, a higher value of the frailty bi is associated with both a
decreased cure probability and an increased hazard of experiencing the event. This
is a natural and plausible way to allow the underlying frailty to affect both cure and
survival.
Following common practice (Duchateau and Janssen (2008)), we assume that the
frailty follows a gamma distribution with shape and scale both equal to 1/θ, ensuring
that E(b) = 1 and Var(b) = θ (θ > 0). Integrating out bi, the marginal survival
8
function is
S˜i(ti) =
∫
Si(ti| bi)f(bi)dbi =
∫
Si(ti| bi) b
1/θ−1
i
e−bi/θθ1/θΓ(1/θ)
dbi
=
(
1
1 + θe−ηpii
)1/θ
+
(
1
1 + θtieησi
)1/θ
−
(
1
1 + θe−ηpii + θtieησi
)1/θ
,(2.2.4)
with corresponding density
f˜i(ti) = e
ησi
[(
1
1 + θtieησi
)1/θ+1
−
(
1
1 + θe−ηpii + θtieησi
)1/θ+1]
. (2.2.5)
Therefore, the log likelihood of the observed data is
l =
∑
i
[di ln f˜i(ti) + (1− di) ln S˜i(ti)], (2.2.6)
where for subject i, ti is the observed time (minimum of event and censoring times)
and di is the indicator that an event has occurred. We can rewrite (2.2.4) as
S˜i(ti) = pii + (1− pii)S˜∗i (ti),
where
pii =
(
1
1 + θe−ηpii
)1/θ
, (2.2.7)
and
S˜∗i (ti) =
(1 + θtie
ησi )−1/θ − (1 + θe−ηpii + θtieησi )−1/θ
1− (1 + θe−ηpii )−1/θ . (2.2.8)
Because S˜∗i (ti) is a proper survival function, the marginal cure fraction is pii and the
marginal non-cured survival function is S˜∗i (ti), with corresponding marginal non-cured
hazard function
h˜∗i (ti) = e
ησi
(1 + θtie
ησi )−1/θ−1 − (1 + θe−ηpii + θtieησi )−1/θ−1
(1 + θtieησi )−1/θ − (1 + θe−ηpii + θtieησi )−1/θ . (2.2.9)
9
We note that the cure probability and hazard given not cured are originally defined
at the subject level, conditional on the frailty. Thus although we have also derived
the marginal cure fraction and non-cure hazard, as a rule we are more interested in
the effects of predictors at the individual level, and we will interpret the parameters
in this conditional sense.
2.2.2 Modeling Repeated Events
One can extend the model to repeated events by using the underlying frailty to
induce dependence among the event times. That is, we assume that for each subject,
given the susceptibility bi the event times are independent with survival function
given by (2.2.2) and (2.2.3). Denoting tij as the length of the j-th episode for subject
i, we have
Sij(tij| bi) = piij(bi) + [1− piij(bi)]S∗ij(tij| bi), (2.2.10)
piij(bi) = exp[−bi exp(−ηpiij)], S∗ij(tij|bi) = exp[−tijbi exp(ησij)], (2.2.11)
where the linear predictors can include both subject-level and episode-level predictors.
The log likelihood is then
l =
∑
i
ln
[∫
exp
(∑
j
lij
)
f(bi) dbi
]
, (2.2.12)
where
lij = dij ln fij + (1− dij) lnSij
= dij ln
(
−∂Sij
∂tij
)
+ (1− dij) lnSij.
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One can in principle derive closed-form expressions for the likelihood terms, but
the derivation quickly becomes tedious as the number of events increases. Moreover,
the analytical formulas involve numerous subtractions among quantities like those
in Equations (2.2.4) and (2.2.5), and therefore may lead to loss of precision when
evaluated numerically. Therefore in our implementation of the model we have relied
on numerical quadrature, which although mathematically only approximate is not
subject to cancelation errors and therefore may be more reliable in practice.
2.2.3 Modeling Alternating States
As we have indicated, subjects in smoking cessation trials transit between smoking
and abstinence, often several times during the course of treatment. Those currently
in state 1 (abstinent) are at risk for events of type 1 (lapse), while those currently in
state 2 (smoking) are at risk for events of type 2 (recovery of abstinence). Hougaard
(2000) terms this situation “alternating states” (Figure 2.1).
To describe such data, we further extend the model by positing the existence of
two correlated frailties (b
(1)
i , b
(2)
i ) for each subject, where b
(k)
i pertains to events of
type k. As in Equations (2.2.10) and (2.2.11), the survival function for episode j of
type k for subject i is
S
(k)
ij (t
(k)
ij |b(k)i ) = pi(k)ij (b(k)i ) + [1− pi(k)ij (b(k)i )]S∗(k)ij (t(k)ij |b(k)i ),
where
pi
(k)
ij (b
(k)
i ) = exp[−b(k)i exp(−η(k)piij )],
S
∗(k)
ij (t
(k)
ij |b(k)i ) = exp[−t(k)ij b(k)i exp(η(k)σij )], k = 1, 2, (2.2.13)
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and η
(k)
ij and σ
(k)
ij refer to the linear predictors for cure fraction and hazard, respec-
tively, of subject i, episode j of type k. To complete the model, we must specify the
joint distribution of the frailties. A popular choice in hierarchical models is the log-
normal, which can flexibly represent a range of complex dependence structures. We
prefer however to use marginal gamma distributions, which are more commonly as-
sociated with frailty models. Smith et al. (1982) proposed a five-parameter bivariate
gamma distribution, but its intractability complicates implementation. An alterna-
tive approach is to apply a copula, which allows for correlation while retaining the
specified marginals. We will use the Clayton copula (Clayton (1978)), whose joint
cumulative distribution function (CDF) is:
F (b
(1)
i , b
(2)
i ) =

max[(F1(b
(1)
i )
−α + F2(b
(2)
i )
−α − 1)−1/α, 0] if α 6= 0,
F1(b
(1)
i )F2(b
(2)
i ) if α = 0;
where Fk(·), k = 1, 2, is the CDF of a gamma (shape=1/θk, scale=1/θk) distribution,
and α is an association parameter defined on (−1,+∞). The copula approaches the
minimum, product and maximum, as α approaches −1, 0 and +∞, respectively. The
parameter α measures the strength of association and is linked to Kendall’s τ by
τ = α/(α + 2). The corresponding density is
f(b
(1)
i , b
(2)
i ) =

(1 + α) max[(F1(b
(1)
i )
−α + F2(b
(2)
i )
−α − 1)−1/α−2, 0]
×F1(b(1)i )−α−1F2(b(2)i )−α−1f1(b(1)i )f2(b(2)i ) if α 6= 0,
f1(b
(1)
i ) f2(b
(2)
i ) if α = 0;
where fk(·), k = 1, 2, is the gamma density with shape and scale both equal to 1/θk.
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The log likelihood is
l =
∑
i
ln
[∫
exp
(∑
j
lij
)
f(b
(1)
i , b
(2)
i )db
(1)
i db
(2)
i
]
, (2.2.14)
where
lij = Indicator(type 1 event) · l(1)ij + Indicator(type 2 event) · l(2)ij ,
l
(k)
ij = d
(k)
ij ln
(
−∂S
(k)
ij
∂t
(k)
ij
)
+ (1− d(k)ij ) lnS(k)ij , k = 1, 2.
2.2.4 Estimation
As indicated above, we advocate computing the likelihood by numerical integra-
tion. A straightforward approach is to use bivariate Gaussian quadrature (Abramowitz
and Stegun (1972)), as implemented, for example, in SAS Proc NLMIXED. Unfor-
tunately, we cannot apply Gaussian quadrature directly in Proc NLMIXED unless
the random effects are normally distributed. Nelson et al. (2006) described a simple
computational method using the probability integral transformation (PIT), and Liu
and Huang (2007) applied it to various frailty proportional hazards models. Recently,
Liu and Yu (2008) proposed another integration method that reformulates the con-
ditional likelihood on non-normal random effects. One can implement both PIT and
likelihood reformulation (LR) in Proc NLMIXED, but we favor LR because it offers
reduced computing times and a potentially broader range of application.
Following the notation in the previous section, the likelihood from subject i is
Li =
∫
exp
(∑
j
lij
)
f(b
(1)
i , b
(2)
i )db
(1)
i db
(2)
i (2.2.15)
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Multiplying and dividing the integrand by the standard bivariate normal density
φ(·, ·) gives
Li =
∫
exp
(∑
j
lij
)
f(ea
(1)
i , ea
(2)
i )ea
(1)
i +a
(2)
i
φ(a
(1)
i , a
(2)
i )
φ(a
(1)
i , a
(2)
i ) da
(1)
i da
(2)
i , (2.2.16)
where a
(k)
i = ln b
(k)
i , k = 1, 2; the extra e
a
(1)
i +a
(2)
i arises from the Jacobian. We can
then apply Gaussian quadrature in SAS Proc NLMIXED to integrate
exp
(∑
j
lij
)
f(ea
(1)
i , ea
(2)
i )ea
(1)
i +a
(2)
i
φ(a
(1)
i , a
(2)
i )
.
Specifically, the new conditional log likelihood for subject i consists of three elements:
lAi =
∑
j
lij,
lBi = ln f(e
a
(1)
i , ea
(2)
i ) + a
(1)
i + a
(2)
i ,
lCi = −0.5 (a(1)i )2 − 0.5 (a(2)i )2 − ln(2pi),
leading to
Li =
∫
exp(lAi + l
B
i − lCi ) φ(a(1)i , a(2)i ) da(1)i da(2)i .
We have obtained maximum likelihood estimates (MLEs) using quasi-Newton op-
timization in SAS Proc NLMIXED, with covariance estimates from inversion of a
finite-differences approximation to the Hessian (Dennis and Schnabel (1983)). As
a check on the validity of standard errors (SEs), we have also computed estimated
sample variances using a parametric bootstrap (Efron and Tibshirani (1993)). Specif-
ically, denoting ξ as the parameter vector, we estimated the model from the actual
data to obtain the MLE ξˆ. We then generated a large number Q of data sets simulated
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under the assumed model with ξ fixed at ξˆ, obtaining from data set q the new esti-
mate ξˆ∗(q). The estimated variance-covariance matrix is then the sample variance of
the bootstrapped estimates ξˆ∗(q) (q = 1, . . . , Q). In simulations, confidence intervals
(CIs) based on bootstrap SEs reliably gave near-nominal coverage probabilities.
2.2.5 A Marginal Approach
An alternative to likelihood-based modeling is a marginal approach (Yu and Peng
(2008)), in which one estimates the model as though the correlated events are inde-
pendent, then constructs a covariance matrix that adjusts for potential correlation
(Williams (2000)). For our model, we assume the survival function for the length T
(k)
ij
of episode j of type k on subject i to be
S˜
(k)
ij (t
(k)
ij ) =
(
1
1 + θ(k)e−η
(k)
piij
)1/θ(k)
+
(
1
1 + θ(k)t
(k)
ij e
η
(k)
σij
)1/θ(k)
−
(
1
1 + θ(k)e−η
(k)
piij + θ(k)t
(k)
ij e
η
(k)
σij
)1/θ(k)
, (2.2.17)
for i = 1, . . . ,m, j = 1, . . . , n
(k)
i , k = 1, 2, where m is the total number of subjects
and n
(k)
i is the number of episodes of type k on subject i. Here η
(k)
piij and η
(k)
σij refer
to linear predictors for subject i, event j of type k, for cure fraction and event rate
given not cured, respectively. Note that the marginal distribution of an event time
T
(k)
ij follows Equation (2.2.17) in all of the models in §2.2.1, §2.2.2 and §2.2.3. But
in §2.2.2 and §2.2.3, the likelihood is calculated based on the joint distribution of
{T (k)ij ; j = 1, 2, . . . , n(k)i }, instead of their marginal distributions.
We denote U(ξˆ) as the estimated score function and I(ξˆ) as the estimated infor-
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mation matrix. Then we estimate the variance-covariance matrix of ξˆ by the Williams
robust estimate I−1(ξˆ)V̂arW (U(ξˆ))I−1(ξˆ), where
V̂arW (U(ξ)) = V̂ar(
m∑
i=1
2∑
k=1
nki∑
j=1
U
(k)
ij (ξ))
=
m
m− 1
m∑
i=1
(Ui(ξ)− U¯(ξ))(Ui(ξ)− U¯(ξ))T , (2.2.18)
U
(k)
ij (ξ) is the score for episode j of type k on subject i, Ui(ξ) =
∑2
k=1
∑nki
j=1 U
(k)
ij (ξ)
is the score function for subject i, and U¯(ξ) =
∑m
i=1 Ui(ξ)/m is the mean of the
individual scores.
Note that observing a set of recurrent event times over a fixed length of observation
C induces dependent censoring in that the censoring time of Tij is C − Ti1 − · · · −
Ti,j−1 (for j ≥ 2) (Huang and Chen (2003); Chen et al. (2004)). Specifically, the
excess of shorter events observed for later episodes (except the first episode) can bias
frequentist data summaries such as marginal model fits and simple Kaplan-Meier
(KM) estimates. But because the data are coarsened at random, in the sense that
censoring times depend only on fully observed data, likelihood-based inferences that
ignore the randomness of the coarsening mechanism are nevertheless valid (Heitjan
and Rubin (1991); Heitjan (1993, 1994)). We will revisit this issue in the simulations.
2.3 Application
The data are from two clinical trials of bupropion for smoking cessation — one
(n = 555) conducted at Georgetown University (Lerman et al. (2002)) and the other
(n = 559) at Brown University (Brown et al. (2007)). Because the designs were
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nearly identical, the two studies have been published in combined analyses (Wileyto
et al. (2005)). Briefly, eligible participants were randomized to receive 10 weeks of
treatment with either sustained-release bupropion (Zyban, 300mg/day) or placebo,
plus seven sessions of in-person behavioral group counseling. Subjects began taking
assigned medication on the day of the first counseling session, and were instructed
to smoke as normal until the target quit date (TQD), scheduled for 14 days after
the initiation of drug treatment. Telephone follow-ups were conducted at the end of
treatment (EOT) and 6 and 12 months post-TQD. Before each counseling session and
during follow-up assessments, participants reported the number of cigarettes smoked
each day since the previous assessment. From the daily cigarette consumption records
we constructed the outcomes time to lapse (a day that includes smoking) and time
to recovery from a lapse (an entire day without smoking).
We restrict our analysis to the treatment phase of the study, an 8-week period
between TQD and EOT. Among the 1114 randomized subjects, 757 succeeded in
quitting on the TQD and 357 failed. Experience has shown that subjects who are
unable to quit on the TQD have sharply different outcome patterns, and therefore
we excluded them from this analysis.
The 757 subjects had varying number of episodes, from 1 to 42. Among them, 314
subjects (42%) had only one episode, implying that they never lapsed during the entire
8 weeks. Ninety-five subjects (13%) had only two episodes, with an average censoring
time 42, implying that they lapsed shortly after the initial quit and then continued
smoking to the end of the study. Most of the rest of the subjects experienced many
episodes with short durations, on average 8 episodes of length 7 days.
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Figure 2.2 depicts the KM curves in the two groups for the two types of events,
disregarding episode number and clustering. This is a rough way to understand the
pattern of the data, because as we have indicated the censoring induces a potential
bias in event times. Nevertheless we see that all curves exhibit an initial rapid decline
followed by a plateau. The recovery events decline steeply to a nearly horizontal
plateau, signaling the existence of a cured fraction. For lapse events the decline is
more gradual and the plateau less perfectly flat, making the hypothesis of a cure
model less certain but still plausible. For lapse events the curve for the intervention
group appears to decline more slowly and to a higher plateau compared to the placebo
group, suggesting possible drug effects on both cure fraction and hazard of lapse given
not cured.
We analyzed the data under three models. First we fit the Independent Frailty
by Episode and Type (IFET) model, which assumes separate, independent frailties
for each event, adjusting for potential correlation using the cluster-correlated robust
variance estimate of Williams (2000) (§2.2.5). The second model (IFT, for Indepen-
dent Frailty by Type) assumes separate, independent frailties by event type (§2.2.2).
That is, we again model the two types of events separately, but let the recurrent
episodes of each type on one subject share a common underlying frailty, as shown
in Equations (2.2.10) and (2.2.11). The third model (CF for Correlated Frailty) ex-
tends IFT by allowing the possibility of correlation between the two frailties through
the gamma Clayton copula (§2.2.3). In all three models we assume that the linear
predictor includes only an intercept and a drug treatment effect. Results appear in
Table 2.1.
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In the IFET model, robust SEs exceed na¨ıve SEs by 9%–48% percent for all param-
eters pertaining to recovery events, whereas for lapse events, robust SEs associated
with the variance and the intercept in the cure component are deflated slightly (15%–
19%). The differences do not affect statistical significance, however. The Akaike
Information Criterion (AIC) suggests a substantially better fit with IFT. Applying
the parametric bootstrap with Q = 20 changes the SEs only slightly and has no effect
on statistical significance. Examination of the CF results reveals that incorporating
the association parameter α has little effect on the parameter estimates or the quality
of the fit; the log likelihood increases by only 0.2 and the AIC by 1.6, and the 95%
Wald CI for α includes 0 ([−0.334, 0.417]). Thus we henceforth restrict attention to
the IFT model.
To check the model fit, we calculated the marginal survival function (Equation
2.2.4) based on the MLEs, for the two types of events and two treatment arms sep-
arately. In Figure 2.3, we compare these fitted marginal survival curves to KM esti-
mates from the first episode only. We limited our analysis to the first episode because
KM estimates from later episodes (j ≥ 2) are potentially biased due to dependent
censoring, as indicated in §2.2.5. The plots suggest that the model fits the data well.
Based on Equation (2.2.7), the estimated marginal cure probabilities for lapse are
0.39 for bupropion and 0.27 for placebo, and for recovery are 0.21 for bupropion and
0.23 for placebo. For recovery events, these estimates are very close to the plateau
levels in the KM plots in Figure 2.3. For lapse events, these estimates are slightly
lower than the graphical estimates, presumably because the curves are not completely
flat by the end of the observation period.
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Based on the IFT model results, bupropion increases the probability of permanent
quit, with cure probability 0.11 for drug and 0.01 for placebo (for a standard indi-
vidual with frailty 1). For non-cured events bupropion reduces the hazard of lapse,
with hazard ratio (HR) 0.56. Bupropion has no significant effect on the probabil-
ity of abandoning quit attempts (0.15 for drug vs. 0.17 for placebo for a standard
individual), nor does it accelerate recovery for those who persist in trying to quit
(HR=1.15 for drug vs. placebo). Note that the individual-level cure probabilities are
quite different from the marginal cure probabilities, especially for lapse events. The
individual and marginal probabilities agree when the frailty variance is zero but can
diverge substantially when the frailty variance increases. For our data the estimated
frailty variances are 1.63 for lapse and 0.26 for recovery, whence the disparity between
marginal and individual quit probabilities.
In the CF model we expected that shorter times to recovery would be correlated
with longer times to relapse, reflecting stronger addiction and implying a negative
association parameter. The estimated α is slightly positive, although not significant.
We postulate that individuals with a heavier addiction may have a stronger impulse
to quit, which induces a higher frailty to recovery, while at the same time the heavy
addiction makes abstinence harder and thus corresponds to a higher frailty to lapse.
2.4 Simulation
We conducted a series of simulations to evaluate the performance of our method
in repeated samples. Each simulation consisted of 100 replications of 800 subjects.
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We fixed the length of follow-up at C = 60 and assigned treatment randomly with
probability 1/2, as in the trial. We chose the parameters to be similar to estimates
from the data: For the lapse parameters, we set the intercept at −1.5 and the drug
coefficient at 0.7, corresponding to a cure probability of 0.01 for placebo and 0.11 for
drug. We set the intercept and drug coefficients in the survival part at −1 and −0.6,
giving a baseline hazard of 0.37 and HR of 0.55 for drug vs. placebo. For recovery
events, we set the intercept and drug coefficients in the cure component to be 0.5 and
−0.1, and those in the survival part to be −1 and 0.1. We fixed the frailty variances
at 1 and 0.3 and the association parameter at 1.
For each simulated subject, we first generated two frailties from the Clayton copula
using function mvdc() from the package copula in R 2.6.2 (Yan (2007)). This gave
an average correlation of 0.35 in the 100 replicates, with range from 0.21 to 0.41.
Next, we generated lapse times T
(1)
j and recovery times T
(2)
j . To incorporate the cure
fraction, we drew random variates R
(k)
j , k = 1, 2 from a Uniform (0,1); if R
(k)
j < pi
(k)
j ,
T
(k)
j was changed to a number beyond the end of study (T
(k)
j = C +10), representing
a “cure”. The recurrent event times were then lined up as: T
(1)
1 , T
(2)
1 , T
(1)
2 , T
(2)
2 , · · · ,
and the cumulative time was used to determine censoring. That is, if the sum Ψl of
times to the l-th event was less than C, and the sum Ψl+1 of times to the l + 1-st
event was greater than C, then the l + 1-st event was censored at C −Ψl. We fitted
the CF model in Proc NLMIXED.
Simulation results appear in Table 2.2. Bias for the CF model is modest, ranging
from−0.010 to 0.014, and all of the estimates except those for α are tightly distributed
around their means. Hessian-based 95% CIs achieve roughly nominal coverage, with
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values ranging from 89% to 98%. Thus the overall performance of the estimates ap-
pears to be satisfactory. Moreover, 94% of the α estimates are significant at level 0.05,
suggesting that the CF model has substantial power to detect a moderate underlying
correlation.
We also fit the IFT model (fixing α = 0) to the simulated data (Table 2.2).
Estimated biases under the incorrect IFT model are 3 to 30 times larger than under
the correct CF model, and the coverage of 95% CIs is much poorer, ranging as low as
39%. Thus the CF model can provide a substantially better fit than the IFT model
when the frailty correlation is moderate.
To better understand the power in testing the significance of α, we conducted two
other simulations (results not shown) where the true α was set to be 0.4 or 0. With
α = 0.4, the numerical correlation is around 0.17, and 29 percent of the α estimates
are significant. With α=0, 10% of the estimates are significant, so the type I error is
somewhat inflated. We also investigated the likelihood ratio test (LRT), which gives
power 95%, 40% and 6% at α=1, 0.4, and 0, respectively, suggesting its superiority
over the Wald test.
To investigate potential bias in the IFET (marginal) model (as suggested in
§2.2.5), we estimated both the IFT and IFET models when α was set to 0 (Ta-
ble 2.3). As expected, biases in the parameter estimates under the IFT model are
small (absolute value 0 to 0.019), whereas biases under the IFET model range as high
as 0.405. Accordingly, 95% CIs have good coverage under the IFT model (91%–97%)
and poor coverage under the IFET model (0%–78%).
Lastly, we estimated the parametric bootstrap SE for the CF model in each sce-
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nario. In all cases it turns out to be close to the Hessian-based SE (± 0.005), with 95%
CIs based on both approaches achieving near-nominal coverage probability. So the
reliability of the simple Hessian-based SE seems adequate in these settings. For some
other parameter values that we investigated, however, the Hessian-based SEs give
reduced coverage probabilities; by contrast, the bootstrap method is well calibrated
in every case.
2.5 Discussion
We have proposed a novel cure-mixture frailty model that allows for correlated
events of alternating types, as one encounters in smoking cessation studies. Our
model is unique in positing that a common frailty influences both the cure fraction
and the survival rate. The use of a cloglog link for the cure fraction and a con-
stant hazard for the non-cured survival offers analytic convenience, but because we
use numerical integration and optimization even with small numbers of events, one
could easily extend the model by substituting other, less tractable link functions and
survival distributions. Moreover, although the models we estimated include only a
randomization indicator in the linear predictor, it is straightforward to incorporate
baseline and episode-specific predictors. In particular, this would allow for estimating
trends across episodes.
Our method offers an alternative to mover-stayer Markov models with alternating
states and a possibility of cure (Cook et al. (2002); Mannan and Koval (2003)) by in-
corporating time-to-event models for correlated outcomes. Use of the Clayton copula
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maintains the simplicity of marginally gamma frailties while avoiding the complexity
of the bivariate gamma. Moreover, as with the link and hazard specification, one can
readily substitute different and more complex frailty models. A potential disadvan-
tage is that with dimension three or higher the Clayton copula allows only positive
association.
As evaluation of the likelihood requires numerical integration in all but the sim-
plest cases, parameter estimation is computationally intensive. We have employed
the LR method of Liu and Yu (2008), implemented in SAS Proc NLMIXED with the
recommended 30 quadrature points and default quasi-Newton optimization. Simula-
tion results suggest that the procedure works well, and moreover we confirmed results
for fitting the IFET model in an independent implementation in R.
In simulations with smaller sample sizes (e.g., m = 200), estimates sometimes
failed to converge. One can avoid this problem by identifying better starting values,
reparameterizing to avoid boundary constraints, or employing a more robust opti-
mization technique such as Nelder-Mead. Changing optimization algorithms should
be a last resort, however, as the default quasi-Newton method typically attains con-
vergence in several minutes compared to possibly several hours for Nelder-Mead.
With this numerically intensive approach, the largest feasible number of simula-
tion replicates was 100, and thus estimates of frequentist operating characteristics
have substantial uncertainty. Nevertheless, we were able to establish that one can
fit the model reliably in samples of practical size, that departures from underlying
assumptions can cause severe bias, and that SEs derived from a finite-differences
estimate of the Hessian can be accurate. Because for some parameter settings the
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Hessian-based SEs underestimated sampling variability, we recommend that in key
analyses one employ the parametric bootstrap, which gave properly calibrated CIs in
every simulation we attempted.
We applied our model to smoking data collected during the relatively brief 8-week
treatment period, where time-to-lapse curves had not reached a plateau and conse-
quently the cure fraction might be poorly estimated. Nevertheless we are convinced
that there is a cured fraction, as evidence from other trials suggests strongly that this
is a real feature of smoking cessation data. It is well known that when cure is a pos-
sibility, failure to incorporate it in the model can cause severe bias in survival hazard
parameters (Sy and Taylor (2000); Price and Manatunga (2001)). The consequences
of incorrectly assuming a cured fraction are perhaps less well known but amenable to
investigation in any specific case. In fact we find that the cure model is most helpful
as an analytic tool when there is enough censoring to create some ambiguity about
it; otherwise, one can easily classify subjects as cured or not and then estimate cure
and survival models directly. Nevertheless, we recommend restricting the use of the
model to problems where the possibility of cure has a strong basis in the science.
There is a growing literature on the analysis of smoking cessation data. Baner-
jee and Carlin (2004) extended cure models to allow for spatial correlation using a
Bayesian approach, and Yu and Peng (2008) applied a univariate cure model, ad-
justing for clustering by a one-step jackknife. Both of these models focused on lapse
events only. Yu and Peng’s model is similar to our IFET model, but substitutes a
jackknife for the sandwich variance estimate. A marginal approach can work well with
clustered survival data but, as our simulations show, is subject to bias when applied
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to recurrent events. Another recent article by Luo et al. (2008) used a discrete-time
stochastic model to describe the transitions among smoking, transient quitting, and
permanent quitting. A major difference with our work is that they model visit-to-
visit transitions of smoking status at lengthy intervals, whereas we model transitions
in more nearly continuous time. Moreover, their model fails to account for the prob-
ability of abandoning the quit attempt.
A potential further application of our model is to estimate individual frailties as
a means of characterizing subjects with respect to amenability to treatment. This is
important because nicotine addiction is most helpfully thought of as a chronic disease
that may take years to successfully treat. Estimating patients’ underlying chances of
success may ultimately lead to better prediction of outcomes and personalization of
therapies.
Although we developed our model to describe cigarette consumption histories in
a randomized smoking cessation trial, it is potentially applicable in observational
studies and in research on cessation of other substances of abuse. The modeling of
alternating states will also be applicable in the study of relapsing-remitting diseases
such as multiple sclerosis and depression, and diseases such as heart failure that
involve repeated hospitalizations.
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Figure 2.1: Alternating states data.
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Figure 2.2: Kaplan-Meier estimates for the two event types, by treatment arms.
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Table 2.1: Parameter estimates from the bupropion data.
IFET IFT CF
Estimate SE(adjusted) Estimate SE Estimate SE
Lapse
Cure fraction
Intercept −1.627 0.210(0.171) −1.479 0.203 −1.475 0.207
Drug 0.669 0.141(0.150) 0.680 0.221 0.681 0.220
Survival model
Intercept −1.581 0.059(0.072) −2.096 0.090 −2.096 0.090
Drug −0.447 0.082(0.126) −0.586 0.122 −0.587 0.122
Variance 0.808 0.125(0.106) 1.634 0.144 1.629 0.157
Recovery
Cure fraction
Intercept −0.734 0.062(0.071) −0.578 0.062 −0.570 0.074
Drug −0.019 0.081(0.088) −0.059 0.091 −0.057 0.091
Survival model
Intercept −0.815 0.048(0.055) −0.932 0.060 −0.942 0.075
Drug 0.117 0.069(0.082) 0.141 0.087 0.140 0.087
Variance 0.201 0.029(0.044) 0.255 0.043 0.261 0.044
Association — — — — 0.041 0.191
Log likelihood −8024.1 −7716.2 −7716.0
AIC 16068.2 15452.4 15454.0
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Figure 2.3: Fitted marginal survival curves and Kaplan-Meier estimates for the first
episode.
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Table 2.2: Results of simulations with α = 1.
CF IFT
True 95 % CI 95 % CI
Parameter value Bias
√
MSE CP (%) Bias
√
MSE CP (%)
Lapse
cure fraction
intercept −1.5 0.010 0.113 93 −0.052 0.127 88
drug 0.7 0.000 0.119 93 0.025 0.123 95
survival model
intercept −1.0 −0.010 0.078 89 0.026 0.082 86
drug −0.6 −0.005 0.095 93 −0.022 0.097 94
variance 1.0 0.001 0.079 96 0.030 0.084 96
Recovery
cure fraction
intercept −0.5 0.000 0.049 97 −0.099 0.108 39
drug −0.1 −0.003 0.072 96 −0.038 0.083 90
survival model
intercept −1.0 0.002 0.056 94 0.099 0.110 41
drug 0.1 −0.006 0.066 98 0.022 0.070 93
variance 0.3 0.004 0.040 95 −0.056 0.063 61
Association 1.0 0.014 0.343 96 — — —
Note: “CP” = Coverage probability.
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Table 2.3: Results of simulations with α = 0.
IFT IFET
True 95 % CI 95 % CI
Parameter value Bias
√
MSE CP (%) Bias
√
MSE CP (%)
Lapse
cure fraction
intercept −1.5 0.019 0.093 97 0.241 0.271 49
drug 0.7 −0.014 0.116 97 −0.117 0.166 72
survival model
intercept −1.0 0.001 0.064 91 0.332 0.340 0
drug −0.6 0.003 0.094 95 0.112 0.148 54
variance 1.0 −0.016 0.099 91 −0.405 0.413 0
Recovery
cure fraction
intercept −0.5 −0.004 0.054 93 −0.252 0.266 2
drug −0.1 −0.008 0.076 95 −0.055 0.100 78
survival model
intercept −1.0 0.001 0.051 95 0.278 0.285 1
drug 0.1 0.000 0.070 95 −0.059 0.101 70
variance 0.3 −0.004 0.039 93 −0.079 0.104 44
Association 0 — — — — — —
Note: “CP” = Coverage probability.
31
Chapter 3
Prediction of Individual
Long-Term Smoking Outcomes
3.1 Introduction
In smoking cessation clinical trials, subjects commonly receive treatment over a
defined length of time (often 8–12 weeks), with follow-up assessments taken at 6 and
12 months after baseline. The outcome at the end of treatment is an important but
imperfect indicator of efficacy, in that some subjects who quit early are unable to
sustain their initial success, whereas some who fail early later succeed. Therefore it
is of interest clinically to predict long-term smoking outcome from short-term data.
And as we indicated in the end of Chapter 2, estimating patients’ underlying chances
of success may ultimately lead to personalization of therapies and optimization of
treatments to reverse short-term failure and sustain short-term success.
The unique features of smoking cessation data complicate statistical analysis, as
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we described in Chapter 2. First, subjects commonly experience a series of lapse and
recovery episodes of varying lengths, alternating between smoking and abstinence.
Moreover, any quit episode may be temporary, followed by a lapse, but it may also
become permanent, in that the subject quits smoking forever. Conversely, any lapse
may be temporary, leading to a recovery, but it may also become permanent, in that
the subject gives up the quit attempt altogether. One can model such possibilities
of permanence by “cure” probabilities in time-to-event models. Another important
feature of such data is heterogeneity, in that outcomes depend critically on unobserved
factors that are not encoded in baseline covariates. We can model such heterogeneity
by random effects, or frailties as they are denoted in survival analysis.
There is a growing statistical literature on the modeling of complex smoking ces-
sation patterns (Cook et al. (2002); Mannan and Koval (2003); Banerjee and Carlin
(2004); Yu and Peng (2008); Luo et al. (2008)). In Chapter 2, we proposed a cure-
mixture frailty model that allows for recurrent, correlated events of two alternating
types, with a possibility of cure in each episode (Li et al. (2010)). Our analysis sought
to provide a more accurate and nuanced representation of the activities of the treat-
ments in question by disentangling their effects on the daily hazards and long-term
cure probabilities of lapse and recovery. Although in our real-data example longer-
term outcomes were collected, we based our analysis on data only from the eight-week
treatment phase.
In this chapter we propose using our model to make long-term predictions. We
develop a two-stage Bayesian algorithm that first imputes frailties then generates pre-
dicted smoking trajectories given the frailties, in both stages conditioning on baseline
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predictors, short-term outcomes and parameter estimates. We illustrate the method
with an analysis of data from two smoking cessation trials we described before, com-
paring our predictions to those from a variety of ad hoc methods. We moreover
perform an array of analyses to evaluate the sensitivity of our predictions to uncer-
tainties in the modeling.
3.2 Review of the Smoking Cessation Trials and
the Cure-Mixture Frailty Model
We use the same data as the analysis in Chapter 2, which come from two random-
ized trials of oral bupropion for smoking cessation. Briefly, subjects who reported
smoking at least 10 cigarettes/day were randomized to receive ten weeks of either
twice-daily bupropion or placebo. All subjects received seven sessions of in-person
behavioral group counseling. The study collected a range of baseline predictors of
smoking behavior, including the Fagerstro¨m Test for Nicotine Dependence (FTND)
score (Heatherton et al. (1991)), the Center for Epidemiologic Studies Depression
(CESD) scale (Radloff (1977)), and race and sex (Dale et al. (2001)).
Participants began taking assigned medication on the day of the first counseling
session, and all were to quit smoking on the target quit date (TQD), two weeks
later. Prior to each counseling session between TQD and the end of treatment (EOT,
eight weeks after TQD) participants reported numbers of cigarettes smoked each day
since the previous assessment, using a time-line follow-back (TLFB) questionnaire.
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From the reported daily cigarette consumption, we constructed for each subject the
on-treatment series of times to lapse (a day that includes smoking) and times to
recovery (an entire day without smoking). Telephone assessment followed at EOT
and 6 months and 12 months post-TQD, where subjects were asked if they had smoked
in the last 7 days. Self-reported quits were verified by tests for smoking by-products
in the breath or saliva. As we indicated in Chapter 2, our analysis will be based on
757 subjects who succeeded in quitting on TQD.
We now review our model for smoking cessation data with alternating states and
cure probabilities (Figure 2.1) (Li et al. (2010)). We denote T
(k)
ij and S
(k)
ij as the event
time and its survival function for episode j of type k for subject i (k = 1 for lapse,
k = 2 for recovery). To incorporate the unobserved risk factors, we assume that
each subject has two latent frailties (b
(1)
i , b
(2)
i ) and conditional on them, the survival
function S
(k)
ij is:
S
(k)
ij (t
(k)
ij |b(k)i ) = pi(k)ij (b(k)i ) + [1− pi(k)ij (b(k)i )]S∗(k)ij (t(k)ij |b(k)i ), (3.2.1)
where
pi
(k)
ij (b
(k)
i ) = exp[−b(k)i exp(−η(k)piij )], (3.2.2)
S
∗(k)
ij (t
(k)
ij |b(k)i ) = exp[−t(k)ij b(k)i exp(η(k)σij )], k = 1, 2. (3.2.3)
That is, each episode either becomes permanent (with probability pi
(k)
ij ) or ends ac-
cording to a proper survival function S
∗(k)
ij (·) (with probability 1 − pi(k)ij ). The linear
predictors η
(k)
piij and η
(k)
σij contain subject-level or episode-level covariates, such as in-
tercept, treatment assignment, and baseline factors.
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We link the two frailties by the Clayton copula (Clayton (1978)), so that their
joint density is
f(b
(1)
i , b
(2)
i ) = (1 + α)[F1(b
(1)
i )
−α + F2(b
(2)
i )
−α − 1]−1/α−2
×F1(b(1)i )−α−1F2(b(2)i )−α−1f1(b(1)i )f2(b(2)i ), (3.2.4)
where Fk(·), k = 1, 2, is the cumulative distribution function (CDF) of a gamma
(shape=1/θk, scale=1/θk) distribution, fk(·), k = 1, 2, is the corresponding gamma
density, and α is an association parameter defined on (−1,+∞).
Letting ξ refer to the parameter vector of covariate effects in the linear predictors,
the frailty variances θk (k = 1, 2) and the association parameter α, one can obtain
the maximum likelihood estimate (MLE) ξˆ using SAS Proc NLMIXED. For details
see Chapter 2.
3.3 Prediction Methods
3.3.1 Sampling Individual Frailties
A natural way to construct predictions is to sample in two stages: First, draw the
subject-level frailties from their posterior distribution; and second, generate individual
future outcomes conditional on the sampled frailties. Denoting the observed data
for subject i as yi ≡ {t(k)ij : j = 1, 2, . . . , ni; k = 1, 2}, and the frailty vector as
bi ≡ {b(1)i , b(2)i }, the posterior distribution of the frailties for subject i is
p(bi|yi, ξ) = p(yi|bi, ξ)f(bi|ξ)∫
p(yi|bi, ξ)f(bi|ξ)dbi . (3.3.1)
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Here f(bi|ξ) is the copula density from (3.2.4), and p(yi|bi, ξ) is the conditional density
of the vector of event times given bi for subject i:
p(yi|bi, ξ) =
∏ni
j=1
(−∂S(1)ij
∂t
(1)
ij
)d(1)ij
·
(
S
(1)
ij
)(1−d(1)ij )δij
×
(−∂S(2)ij
∂t
(2)
ij
)d(2)ij
·
(
S
(2)
ij
)(1−d(2)ij )1−δij , (3.3.2)
where d
(k)
ij , k = 1, 2, is the indicator that an event has occurred; and δij is the indicator
that the episode is of the first type (time to lapse). The numerator can be readily
calculated, but the integral in the denominator cannot. To avoid this complication
we resort to importance sampling (Tanner (1993)).
Importance sampling proceeds as follows: First, one designates an approximate
posterior p∗(bi) from which one can readily sample and whose density is easy to
calculate. One then generates a large number (say, M) of sample draws b
[m]
i , m =
1, . . . ,M , from this distribution. At each sampled value, one computes the true value
of a function proportional to the posterior density (the numerator) and the value of
the approximate posterior density. Their ratio r[m] is then normalized as w[m], which
becomes a weight for use in subsequent calculation:
r[m] =
p(yi|b[m]i , ξ)f(b[m]i |ξ)
p∗(b[m]i )
, w[m] =
r[m]∑M
m=1 r
[m]
. (3.3.3)
To generate a posterior sample of bi one can use sampling/importance resampling
(SIR) (Rubin (1987)). In SIR, one first drawsM values by importance sampling, then
selects Q of these, Q¿M , with replacement using probabilities w[m]. The Q values
so selected (b
∗[q]
i , q = 1, . . . , Q) represent a random sample from an approximation to
the target posterior (Rubin (1987); Smith et al. (1982)).
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One could also calculate some summary measures of bi from its posterior distribu-
tion. For example, to calculate the posterior mean of a function g(bi), one evaluates
the function at all sampled values of bi, say g(b
[m]
i ), m = 1, . . . ,M . The approximate
mean is then
E[g(bi)] ≈
M∑
m=1
w[m]g(b
[m]
i ). (3.3.4)
For example, the posterior mean of the first frailty b
(1)
i can be simply approximated
by
∑M
m=1w
[m]b
(1)[m]
i .
3.3.2 Predicting Future Outcomes
To predict the outcome at one year post-TQD for subject i, we first obtain poste-
rior samples of bi using SIR and then generate the transition times after EOT under
the assumed model with ξˆ and individual frailties b
∗[q]
i (q = 1, . . . , Q). If this subject’s
last observation is an event time, the generating procedure is straightforward: Set the
next event type to be opposite to the last observed event and generate a sequence
of events of alternating types: T
(k)
ij . To incorporate the cure probability, we draw a
sequence of random variates from a Uniform (0, 1); if the jth variate of type k in the
sequence is less than pi
(k)
ij , we re-set T
(k)
ij = ∞, representing a “cure”. The recurrent
event times are then lined up as T
(1)
i1 , T
(2)
i1 , T
(1)
i2 , T
(2)
i2 , · · · , and the cumulative time is
used to determine the censoring.
If subject i’s last observation is censored, we must first simulate whether this
episode is permanent or temporary. Denoting the last observed censoring time as ti,
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the conditional cure probability given observed data is
pii = Pr(cured|T (k)ij > ti) =
Pr(cured)
Pr(T
(k)
ij > ti)
=
pi
(k)
ij
pi
(k)
ij + (1− pi(k)ij )S∗(k)ij (ti)
. (3.3.5)
Again we draw a random variate from Uniform (0, 1). If it is less than pii, the last
observed status is permanent and no further events are generated; otherwise, we
generate further episodes by the above procedure, with the starting event type the
same as the last observed event type. Because given the frailties the event times
are exponential, the conditional distribution of the time from EOT until the first
post-EOT event is the same as if the time origin for the event were at EOT.
Because we derive the event times from daily smoking records, the smallest time
unit is one day. Thus although in principle the last pre-EOT episode should always
be censored, in practice some subjects’ last episode is an event. Moreover with our
model of continuous times, there is a possibility of multiple events within one day.
We therefore reconstruct the simulated data so that the transition times are in units
of days. Specifically, we decide the daily smoking status based on t
(k)
ij , applying the
rule that any smoking during a day indicates non-abstinence (Figure 3.1). We then
obtain the subject’s smoking status (1 for smoking, 0 for non-smoking) at one year
by evaluating whether the simulated last seven days are all smoke-free. This renders
predictions comparable to the actual verified outcomes.
Repeating this process Q times, we obtain Q draws from an approximate predic-
tive posterior. We estimate the individual probabilities of smoking pi by counting the
proportion of draws that find subject i smoking within seven days of the one-year
milestone. These predictive probabilities are in fact samples from the predictive pos-
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terior distribution and henceforth is referred to as the SPP method. We then compare
our predictions to the true, verified values of smoking at one year and estimate an
ROC curve (Fawcett (2006)). Specifically, we apply different thresholds to pi and
for each we calculate the sensitivity and specificity. We obtain the ROC curve by
connecting the points, using AUC (area under the curve) as an index of predictive
accuracy (Hanley and Mcneil (1982)).
We have compared our predictions under the frailty model to predictions from a
range of logistic regression models estimated using the year one outcomes (see the
detailed description below). As such models are predicting the same outcomes on
which they were developed, they are subject to over-fitting. In these cases we applied
a bootstrap correction to adjust the AUC (Harrell et al. (1996)).
Analysis was done in R 2.6.2.
3.4 Results
3.4.1 Model Selection
We first fit the frailty model to the treatment period data to generate a best-fitting
model for the short-term outcomes. Following previous work (Wileyto et al. (2005)),
we dichotomized FTND to be positive if the raw score ≥ 6 (representing greater
dependence) and CESD to be positive if the raw score ≥ 16 (representing more severe
depression). To allow for potential time trends within subjects, we included episode
number and its interaction with treatment as predictors. We recoded episode number
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for each type of event as 1, 2, 3 and ≥ 4 to attenuate the influence of a handful of
subjects who had many episodes. We deleted data from six subjects who had missing
predictors, leaving us with 751 observations.
Because estimating the joint model is numerically demanding (i.e. CF model in
Chapter 2), our initial screening analyses fit separate models for lapse and recovery
events (i.e. IFT model in Chapter 2). For each type of event, we began with a
saturated model including drug, sex, race, FTND, CESD, episode number and the
episode-by-treatment interaction. We then reduced the model in a backward fashion,
eliminating variables whose p-values were larger than 0.05. This procedure removed
race, CESD and the episode-by-treatment interaction for both types of episode, indi-
cating no association of outcome with race and depression, and no differential effect
of treatment across episodes. The remaining variables were then included in a joint
model for the two types of event.
Table 3.1 shows estimates from the selected model. Bupropion increases the
chance of permanent cure and decreases the hazard of lapse, with hazard ratio (HR)
e−0.609=0.54. Female sex is associated with a smaller chance of permanent cure and
a higher hazard of lapse (HR=e0.243=1.28). The cure probability does not change
significantly over time, but the hazard of lapse increases, with HR e0.146=1.16 for
episode j vs. episode j − 1. For recovery events, bupropion has no significant ef-
fect on the probability of abandoning quit attempts, nor does it accelerate recovery
for those who persist in trying to quit (HR=e0.128=1.14). Subjects with elevated
FTND are more likely to give up, and have longer time to recovery even if they
persist (HR=e−0.198=0.82). The probability of abandoning quit attempts increases
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over time, and the hazard of recovery decreases (HR=e−0.105=0.90 for episode j vs.
episode j − 1). Even after controlling for these baseline factors there is substantial
variability in the data (reflected by the frailty variance estimates), but no significant
association between the lapse and recovery frailties.
3.4.2 Sampling Individual Frailties
We approximated the posterior distribution of the frailties for each subject, given
the observed data and parameter estimates from the final model. We used indepen-
dent gamma distributions with mean 1 and variance θˆk, k = 1, 2, as the approximating
proposal distribution p∗(bi) for the importance sampling. To secure better coverage
of the tails of the true posterior, we multiplied the approximate variance by 2. We
then generated M = 8, 000 draws from this gamma distribution and calculated the
importance ratios. Finally, we sampled from the posterior using SIR with Q = M/10
(Smith and Gelfand (1992)).
We conducted some diagnostic evaluations of the quality of the importance sam-
pling approximation: First, we calculated posterior means for various values of M
to determine whether they had stabilized (Tanner (1993)). Second, we varied the
scale factor for the approximation to see whether increasing it affected the estimates
(Tanner (1993)). Third, we examined the histogram of the log importance weights,
where a long right tail suggests that the approximation may be deficient (Gelman et
al. (1995)). We also applied the method to one simulated data set where we knew the
true frailties. We then estimated the frailties by the posterior mean and compared
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them to the true values. Points in the scatter plot of estimated by true frailties lay
close to the 45◦ line, suggesting the method is adequate.
We illustrate the result of the sampling for one subject in Figure 3.2. For each
frailty, the solid line depicts its log marginal prior density, and the dashed line depicts
a smoothed approximation to its log marginal posterior density.
3.4.3 Probabilities of Permanent Recovery and Lapse
We generated transition times after EOT conditional on the sampled frailties. An
important feature of this process is the possibility of permanence for an episode. At a
given time, a subject can be in one of four states: permanently recovered, temporarily
recovered, temporarily lapsed and permanently lapsed. The probabilities of the two
permanent states are of particular interest. From the real clinical data, it is impossible
to tell whether a status is temporary or permanent, but in the simulated data we can
distinguish them. We therefore evaluated each subject’s status every two weeks after
EOT and averaged them across 800 SIR samples to obtain estimated probabilities of
permanent recovery and lapse.
Figure 3.3 shows these probabilities for three selected subjects in each arm. We
note that because both permanent states are absorbing, the probabilities increase over
time. Moreover subjects in the same arm can have quite different “cure” probabilities.
For example, subject 1 in the bupropion arm transited 22 times between smoking and
abstinence, with the final event being a lapse. Thus this subject struggled to make a
sustained quit attempt, and eventual failure is the most likely outcome. Compare the
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graph from subject 8, who never lapsed during the entire eight weeks of treatment
and is very likely a permanent success. In the placebo group, subject 46 abstained
for 10 days, relapsed for 33, then made a second quit attempt of 14 days that was
censored at EOT. This subject therefore had a moderate probability of permanent
recovery (0.4). By contrast, the situation for subject 15 is very clear — after a brief
one day quit he smoked till EOT, and thus was almost certainly a failure.
Figure 3.4 shows the graphs averaged across subjects within treatment arms. The
bupropion arm has a high probability of permanent recovery (0.63) and a relatively
low probability of permanent lapse (0.36). These figures are reversed in the placebo
arm (0.44 for permanent recovery; 0.55 for permanent lapse), reflecting a strong
treatment effect. Note that because the probabilities for both arms sum nearly to 1,
the model suggests strongly that the vast majority of subjects will have reached an
absorbing state by the end of one year.
3.4.4 Predicting One-Year Outcomes
We predicted the probability of smoking at one year using samples from the pre-
dictive posterior distribution as described (the SPP method). Using the predictive
probabilities and actual outcomes for all the subjects, we constructed the ROC curve
and calculated its AUC. For comparison, we considered predictions from three logis-
tic models: The first, lr.frailty, includes baseline covariates and individual estimated
mean frailties from their posterior distribtuion; the second, lr.baseline, includes base-
line covariates only; the third, lr.eot, includes baseline covariates and the smoking
44
status at EOT, defined as abstinence in the week leading up to EOT. As we indicated
above, because we estimated these models using the actual year one outcome, we
calculated a bootstrap-adjusted AUC to penalize for over-fitting.
Results appear in Figure 3.5. Model lr.frailty gives the best predictions (AUC =
0.825, adjusted AUC = 0.811), suggesting that the underlying unobserved individual
frailties are helpful in predicting the outcome. The ROC of lr.baseline is only slightly
above the diagonal (AUC = 0.540, adjusted AUC = 0.501), indicating that baseline
covariates are useless for predicting outcomes. The methods lr.eot and SPP are much
superior to lr.baseline, although slightly inferior to lr.frailty. Because the logistic
regression models use the actual outcome to estimate parameters, whereas SPP uses
only data from the treatment phase, SPP would have a substantial advantage in real
applications. The logistic models would not be beneficial in practice unless one had
a prior data set that gave valid parameter estimates, which in many contexts would
be unattainable.
To investigate whether we can predict the outcome at an earlier point in the
treatment period, we built two other cure-mixture frailty models using only 2-week
and 4-week data, then generated the probability of smoking at one year post-TQD
using the SPP approach. Figure 3.6 shows that the prediction using less information
is not as good as that using the full treatment period, but still is far superior to
predictions using baseline data only. Evidently the subjects already exhibit distinctive
quit patterns by Week 4, so that we gain relatively little by observing them for four
weeks more.
As our approach fixed the model parameters at the MLE ξˆ, it failed to account
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for uncertainty of estimation. To explore sensitivity to this feature of our method,
in a separate analysis we sampled values of ξ from a multivariate t distribution with
location ξˆ, dispersion matrix V̂ar(ξˆ), and degrees of freedom 5. For each draw, we
sampled one complete set of trajectories. The predictive probabilities were very simi-
lar to those from the simpler version (Figure 3.7), and ROC curves mostly overlapped,
with AUC changing by no more than 4%.
We note moreover that our model implicitly made the questionable assumption
that the drug effect, observed only over eight weeks of treatment, persists 10 months
more into the future. Therefore in another analysis, we coded drug as 0 after EOT
for all the subjects, assuming that the drug has no lingering effect. In the resulting
predictions, subjects in the placebo group had identical predictive probabilities as
before, since they were not affected by assumptions about drug effect, but subjects in
the drug group had slightly higher predictive probabilities (on average 0.06 increase).
Nevertheless, the ROC curves were almost the same, with no change in AUC.
3.5 Discussion
We have described a prediction method based on a cure-mixture frailty model for
smoking cessation trials. Although such models have been used in various contexts,
most work has focused on making population inferences and little has been done
on predicting individual future outcomes. Lack of software is a potential obstacle.
For example, SAS Proc NLMIXED yields frailty estimates based on the posterior
mode, but its method is applicable only in the case of normally distributed random
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effects, and only the posterior mode is available rather than the complete posterior
distribution.
Recently, Luo et al. (2009) proposed a Bayesian model for smoking behavior that
predicts subject-specific probabilities using a discrete-time mixed model with a latent
cured state. Our model differs from theirs in accommodating a more nearly continuous
time scale and assuming a cure model for recovery as well as lapse. Moreover, they
did not validate their predictions in a real data application or compare it to more
conventional ad hoc methods, as we did. Our approach is also far less computationally
intensive.
In our application, we chose importance sampling/SIR over other popular sam-
pling methods such as Markov Chain Monte Carlo (MCMC). Our rationale is that
importance sampling/SIR is simple to implement and avoids the issues of testing for
convergence of the Markov chain. A potential drawback is its reliance on the choice
of the approximating distribution — a poor choice can lead to inefficiency or even
bias in posterior moments. To address this concern we evaluated several numerical
diagnostics and also proved the validity of our approximate distribution analytically
(see Appendix 3.6).
Our prediction methods perform reasonably well in terms of AUC, but sensitivity
is generally not as good as specificity; that is, the predictions tend to under-estimate
the probability of smoking at one year. One explanation is that the self-reported
daily cigarette counts have inherent bias. It is not unusual for objective biochemical
tests to contradict subject reports of abstinence (Gorber et al. (2009)). Therefore, our
method potentially offers more accurate prediction if better data records are available.
47
3.6 Appendix: The Validity of the Approximate
Distribution in Importance Sampling
We denote w(b) as the weight function, which is the ratio of the true posterior
distribution p(b|y, ξ) and the approximate distribution p∗(b). We will prove that
E[w(b)] is finite and thus the approximation based on importance sampling is accurate
(Geweke (1989)). We prove the result initially for b(1) marginally; the same proof
applies to b(2).
The marginal posterior density of b(1) is:
p(b(1)|y, ξ) = p(y|b
(1), ξ)f(b(1)|ξ)∫
p(y|b(1), ξ)f(b(1)|ξ)dbi = k1 · p(y|b
(1), ξ)f(b(1)|ξ), (3.6.1)
where k1 is a constant. Recall that we propose f(b
(1)|ξ) as the approximate distribu-
tion, leading to the weight function
w(b(1)) =
p(b(1)|y, ξ)
f(b(1)|ξ) = k1 · p(y|b
(1), ξ), (3.6.2)
and
E[w(b(1))] =
∫ ∞
0
w(b(1))p(b(1)|y, ξ)db(1) =
∫ ∞
0
k21 · p2(y|b(1), ξ) · f(b(1)|ξ)db(1). (3.6.3)
Since we are considering the function of the first frailty b(1) here, all the terms
involving the second type of event will contribute only a constant, so that
p(y|b(1), ξ) = k2 ·
n∏
j=1
(
−∂S
(1)
j
∂t
(1)
j
)d(1)j
·
(
S
(1)
j
)(1−d(1)j )
= k2 ·
n−1∏
j=1
(
−∂S
(1)
j
∂t
(1)
j
)
· S(1)n , (3.6.4)
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where k2 is a constant and the last equation holds because only the last event is
censored. We have
−∂S
(1)
j
∂t
(1)
j
= (1− pi(1)j ) · exp[−b(1) exp(η(1)σj )t(1)j ] · b(1) exp(η(1)σj )t(1)j
< exp[−b(1) exp(η(1)σj )t(1)j ] · b(1) exp(η(1)σj )t(1)j
= exp(−b(1)cj)b(1)cj; (3.6.5)
and
S(1)n = pi
(1)
n + (1− pi(1)n ) exp[−b(1) exp(η(1)σn )t(1)n ]
< exp[−b(1) exp(η(1)σn )t(1)n ]
= exp(−b(1)cn), (3.6.6)
where cj, j = 1, 2, · · · , n, are constants. Plugging (3.6.5) and (3.6.6) into (3.6.4)
yields
p(y|b(1), ξ) < k2 ·
n−1∏
j=1
exp(−b(1)cj)b(1)cj · exp(−b(1)cn)
= k2 exp(−b(1)
n∑
j=1
cj)(b
(1))n−1
n−1∏
j=1
cj
= k3 exp(−b(1)k4)(b(1))k5 , (3.6.7)
where k3, k4 and k5 are positive constants. Therefore,
k21 · p2(y|b(1), ξ) · f(b(1)|ξ)
< k21 · k23 exp(−2k4b(1))(b(1))2k5 ·
(b(1))1/θ
(1)−1 exp(−b(1)/θ(1))
Γ(1/θ(1))(θ(1))1/θ(1)
=
k21 · k23
Γ(1/θ(1))(θ(1))1/θ(1)
· exp[−(2k4 + 1/θ(1))b(1)] · (b(1))2k5+1/θ(1)−1
= k6 exp(−k7b(1))(b(1))k8−1, (3.6.8)
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where k6, k7 and k8 are positive constants.
Note that exp(−k7b(1))(b(1))k8−1 is the kernel of a gamma density, so the integral
of this function over [0,∞) is finite, and accordingly
E[w(b(1))] =
∫ ∞
0
k21 · p2(y|b(1), ξ) · f(b(1)|ξ) db(1) (by (12))
<
∫ ∞
0
k6 exp(−k7b(1))(b(1))k8−1 db(1) (by (17))
< ∞. (3.6.9)
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Table 3.1: Parameter estimates in the selected cure-mixture frailty model.
Estimate SE P-value 95% CI
Lapse
Cure fraction
Intercept −1.185 0.322 <0.001 [−1.818, −0.552]
Drug 0.671 0.184 <0.001 [0.310, 1.032]
Sex: female −0.646 0.187 <0.001 [−1.014, −0.278]
Episode number 0.078 0.091 0.389 [−0.100, 0.257]
Survival model
Intercept −2.561 0.130 <0.001 [−2.815, −2.306]
Drug −0.609 0.120 <0.001 [−0.845, −0.373]
Sex: female 0.243 0.120 0.043 [0.008, 0.478]
Episode number 0.146 0.031 <0.001 [0.084, 0.207]
Variance 1.439 0.222 <0.001 [1.003, 1.876]
Recovery
Cure fraction
Intercept −1.072 0.158 <0.001 [−1.382, −0.763]
Drug −0.045 0.101 0.656 [−0.243, 0.153]
FTND 0.397 0.105 <0.001 [0.191, 0.602]
Episode number 0.116 0.039 0.003 [0.040, 0.193]
Survival model
Intercept −0.648 0.139 <0.001 [−0.920, −0.375]
Drug 0.128 0.099 0.195 [−0.067, 0.323]
FTND −0.198 0.097 0.041 [−0.389, −0.008]
Episode number −0.105 0.029 <0.001 [−0.161, −0.049]
Variance 0.407 0.077 <0.001 [0.256, 0.558]
Association 0.245 0.291 0.401 [−0.327, 0.816]
Figure 3.1: Reconstructing continuous time to daily smoking status.
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Figure 3.2: Frailty distributions for one subject.
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Figure 3.3: Probabilities of permanent recovery and lapse for different subjects. Solid
line indicates probability of permanent recovery; dashed line indicates probability of
permanent lapse.
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Figure 3.4: Probabilities of permanent recovery and lapse in two treatment arms.
Solid line indicates probability of permanent recovery; dashed line indicates proba-
bility of permanent lapse.
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Figure 3.5: ROC curves for predictions using a variety of methods. SPP, AUC=0.782;
lr.frailty, AUC=0.825, adjusted AUC=0.811; lr.baseline, AUC=0.540, adjusted
AUC=0.501; lr.eot, AUC=0.759, adjusted AUC=0.738.
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Figure 3.6: ROC curves for predictions using 2, 4, 8 week data. SPP-8wk,
AUC=0.782; SPP-4wk, AUC=0.728; SPP-2wk, AUC=0.700; lr.baseline, AUC=0.540,
adjusted AUC=0.501.
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Figure 3.7: Predictive probabilities from two versions of sampling. p1: with model
parameters fixed at the MLE; p2: with model parameters sampled from a multivariate
t approximate posterior distribution.
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Chapter 4
A Complementary Mixture Pareto
II Distribution
4.1 Introduction
In a typical survival analysis, we assume that all subjects will eventually experience
the event of interest if followed for a sufficiently long time. In some cases, however,
it is preferable to entertain models that allow a fraction of subjects to be considered
cured, or insusceptible, in the sense that their survival time for the event in question is
essentially infinite. These “cure” models are useful in a number of applied contexts,
including pediatric oncology, where a fraction of patients can be effectively cured
of their disease in the sense that they will never experience a recurrence. Another
useful modeling concept in survival analysis is the frailty model, which arises when
one assumes that a single, latent random effect (or frailty) simultaneously affects
an array of possible survival outcomes on a subject. A setting where both frailties
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and cure models are relevant is smoking cessation trials, where subjects may make a
series of quit attempts over a treatment period, each episode potentially resulting in a
permanent success. Because the durations of an individual’s repeated quit attempts
are potentially correlated, one might also incorporate frailties in the modeling.
In Chapter 2, we proposed a novel cure-mixture frailty model that we applied to
data from two smoking cessation clinical trials (Li et al. (2010)). Our research sug-
gests that the distribution for survival given not cured arising under this model has
not previously been described in the statistical literature. Therefore in this chapter
we present a more detailed analysis of the distribution, which we denote the Comple-
mentary Mixture Pareto II distribution.
Let X denote an event time and S(x) its survival function. We assume that with
probability 1− pi the event time is finite, so that S(x) takes the form
S(x) = pi + (1− pi)S∗(x), (4.1.1)
where S∗(x) is a proper survival function. We assume moreover that, conditional on
a latent random frailty γ, the cure probability and survival function given not cured
take the following forms:
pi(γ) = exp(−γe−ηpi), S∗(x|γ) = exp(−xγeησ), (4.1.2)
where ηpi is a linear predictor for the cure probability, and ησ is a linear predictor for
event rate given not cured. That is, we assume that conditionally on the frailty γ the
probability of cure follows a generalized linear model with a complementary log-log
(cloglog) link; that survival given not cured is exponential with a proportional hazard
regression; and that the natural log of γ affects both linear predictors with coefficient
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1. We moreover assume that the frailty γ represents a random draw from a gamma
distribution with shape and scale both equal to 1/θ. If the cure probability were fixed
at 0, this would be the standard model of a gamma-distributed exponential hazard
(Duchateau and Janssen (2008)).
This cure-mixture frailty model is unique in two respects: First, it assumes the
cloglog function instead of ubiquitous logistic link to model the cure probability; and
second, the underlying frailty γ affects both the cure probability and the hazard given
not cured. These assumptions lead to analytical simplification when we integrate out
the frailty γ in (4.1.1) and (4.1.2) to obtain the marginal survival function
S˜(x) =
∫
S(x)dF (γ) = pi + (1− pi)S˜∗(x), (4.1.3)
where
pi =
(
1
1 + θe−ηpi
)1/θ
, (4.1.4)
and
S˜∗(x) =
(1 + θxeησ)−1/θ − (1 + θe−ηpi + θxeησ)−1/θ
1− (1 + θe−ηpi)−1/θ . (4.1.5)
Note that S˜∗(x) is monotone decreasing with S˜∗(0) = 1 and S˜∗(+∞) = 0, so
that S˜∗(x) is a proper survival function. Therefore the marginal cure probability
is pi and the marginal survival function given not cured is S˜∗(x). The conditional
cure probability and non-cured survival in (4.1.2) are defined at the individual level,
whereas the marginal cure probability and non-cured survival in (4.1.4) and (4.1.5)
represent average population quantities.
Because S˜∗(x) is a proper survival function, it is of interest to know whether it
belongs to any existing family of survival distributions, and if not, to identify its
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unique properties. The remainder of this chapter is devoted to an investigation of
the characteristics of a random variable X following the survival function S˜∗(x). The
discussion will invoke these densities:
Exponential (λ):
f(x) = λe−λx, x ≥ 0, λ ∈ (0,∞); (4.1.6)
Pareto I (α, σ):
f(x) =
α
σ
(
x
σ
)−(α+1)
x ≥ σ, α ∈ (0,∞), σ ∈ (0,∞); (4.1.7)
Pareto II (µ, σ, ξ):
f(x) =
1
σ
(
1 + ξ
x− µ
σ
)−(1/ξ+1)
x ≥ µ, µ ∈ (−∞,∞), σ ∈ (0,∞), ξ ∈ (0,∞). (4.1.8)
4.2 General Characteristics
For simplicity, we denote a = eησ , b = eηpi , c = 1− (1 + θ/b)−1/θ; then
S˜∗(x) =
1
c
[(1 + θax)−1/θ − (1 + θ/b+ θax)−1/θ],
x ≥ 0, a ∈ (0,∞), b ∈ (0,∞), θ ∈ (0,∞). (4.2.1)
Here a is a parameter associated with the conditional hazard (conditional on the
frailty) given not cured; a higher value of a implies a higher conditional hazard of ex-
periencing the event. Parameter b is associated with the conditional cure probability,
where a larger value implies a larger conditional cure probability. The term θ is the
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variance of the frailty, and c is a normalizing constant. The corresponding marginal
density is
f˜ ∗(x) =
a
c
[(1 + θax)−1/θ−1 − (1 + θ/b+ θax)−1/θ−1], x ∈ (0,∞), (4.2.2)
and the hazard function is
h˜∗(x) = a
(1 + θax)−1/θ−1 − (1 + θ/b+ θax)−1/θ−1
(1 + θax)−1/θ − (1 + θ/b+ θax)−1/θ x ∈ (0,∞). (4.2.3)
We can rewrite (4.2.2) as
f˜ ∗(x) =
1
c
· a(1 + θax)− 1θ−1 − (1 + θ/b)
− 1
θ
c
· a
1 + θ/b
(
1 +
θa
1 + θ/b
x
)− 1
θ
−1
= αf1(x)− βf2(x), (4.2.4)
where
α =
1
c
, β =
(1 + θ/b)−
1
θ
c
;
f1 ∼ Pareto II
(
µ = 0, σ =
1
a
, ξ = θ
)
,
f2 ∼ Pareto II
(
µ = 0, σ =
1 + θ/b
a
, ξ = θ
)
.
and
α > 1, β > 0, α− β = 1.
So our density can be represented as a weighted sum of two Pareto II densities, with
the difference of the weights equal to 1. We therefore denote it as the Complementary
Mixture Pareto II distribution (CMPII).
Note that the first derivative of the density is
f˜ ∗
′
(x) = −a
2(1 + θ)
c
[
(1 + θax)−(
1
θ
+2) −
(
1 +
θ
b
+ θax
)−( 1
θ
+2)]
< 0, ∀a, b, θ, x,
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so that the density function is always decreasing with time x.
Figure 4.1 plots the log density and log hazard function at different values of a
and θ when b = 1. Figure 4.2 depicts how the density and hazard function vary with
b when a and θ are held fixed. Note that at any given time point, the hazard function
increases with b and appears to converge to a distribution when b→∞. In fact,
lim
b→∞
S˜∗(x) = lim
d→0
(1 + θax)−1/θ − (1 + dθ + θax)−1/θ
1− (1 + dθ)−1/θ = limd→0
J1
J2
.
Because limd→0 J1 = limd→0 J2 = 0, we have
lim
b→∞
S˜∗(x) = lim
d→0
∂J1/∂d
∂J2/∂d
= lim
d→0
(1 + dθ + θax)−
1
θ
−1
(1 + dθ)−
1
θ
−1 = (1 + θax)
− 1
θ
−1, (4.2.5)
which is a Pareto II distribution (µ = 0, σ = 1
a(1+θ)
, ξ = θ
1+θ
).
4.3 The Special Case of b→ 0
Letting b→ 0 in (4.2.1), the marginal non-cured survival function becomes
lim
b→0
S˜∗(t) = (1 + θat)−
1
θ , (4.3.1)
which is a Pareto II distribution (µ = 0, σ = 1/a, ξ = θ). This is the same as
the marginal survival function arising from the standard frailty model (without cure
probability) with exponential baseline hazard (Duchateau and Janssen (2008)). This
is because when b→ 0, the conditional cure probability goes to 0 in our cure-mixture
frailty model (4.1.1), so that our model reduces to a standard frailty model with
constant hazard conditional on the frailty. In this case, the density function is
f˜ ∗(x) = a(1 + θax)−(
1
θ
+1), (4.3.2)
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with first derivative
f˜ ∗
′
(x) = −a2(1 + θ)(1 + θax)−( 1θ+2) < 0, ∀a, θ, x,
so that the density function is always decreasing with time x.
Figures 4.3 and 4.4 depict the log density and hazard functions at different pa-
rameter values of a and θ when b→ 0. We see that when θ is fixed and a decreases,
the density function decreases at a slower rate, and the hazard is smaller at any given
time. This is because a smaller value of a implies a smaller individual-level condi-
tional hazard, which manifests itself as a smaller population-level marginal hazard.
In particular, when a → 0, the marginal hazard also goes to 0. When a → ∞, the
marginal non-cured survival becomes
lim
b→0,a→∞
S˜∗(x) = (θax)−
1
θ , (4.3.3)
which is a Pareto I distribution (α = 1/θ, σ = 1/(θa)).
Similarly, the density and hazard function vary with θ when a is fixed. It is
interesting to note that the log density is a linear function of time and the hazard is
constant when θ is close to 0. This is because θ → 0 means that the variance of the
frailty also approaches 0, which implies that there is no between-subject heterogeneity,
and therefore the population survival function equals the individual survival function,
which is exponential with constant hazard. That is,
lim
b→0,θ→0
S˜∗(x) = e−ax, (4.3.4)
which is the exponential distribution with λ = a.
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We summarize the relationships of CMPII with other known distributions in Fig-
ure 4.5.
4.4 Characteristic Function and Moments
We first derive the expectation and variance of the CMPII distribution.
Theorem 1. The expectation of a variate X following the CMPII distribution is
E(X) =
1
a(1− θ) ·
1− (1 + θ/b)− 1θ+1
1− (1 + θ/b)− 1θ , θ < 1.
The second moment is
E(X2) =
2
a2(1− θ)(1− 2θ) ·
1− (1 + θ/b)− 1θ+2
1− (1 + θ/b)− 1θ , θ < 1/2,
and therefore the variance is
Var(X) =
2
a2(1− θ)(1− 2θ) ·
1− (1 + θ/b)− 1θ+2
1− (1 + θ/b)− 1θ −
1
a2(1− θ)2 ·
[
1− (1 + θ/b)− 1θ+1
1− (1 + θ/b)− 1θ
]2
, θ < 1/2.
See the Appendix 4.6.1 for a proof. We note that the second factor in the expec-
tation formula is always smaller than 1, so that the expectation satisfies
E(X) <
1
a(1− θ) = E(X1 ∼ f1). (4.4.1)
We next derive the characteristic function EX(e
itx), where i is the square root of
−1.
Theorem 2. The characteristic function of the CMPII distribution is
φ(t) =
1
cθ
(
− it
θa
) 1
θ
[
exp
(
− it
θa
)
Γ
(
−1
θ
,− it
θa
)
−exp
(
−it(1 + θ/b)
θa
)
Γ
(
−1
θ
,−it(1 + θ/b)
θa
)]
.
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Here Γ(·, ·) is the upper incomplete Gamma function, defined as
Γ(s, z) =
∫ ∞
z
ts−1e−tdt,
where s and z are complex parameters (Temme (1996) and Paris (2002)).
As is well known, the characteristic function can be used to calculate nth moments
of a random variable X:
EXn = i−n
∂φn
∂tn
∣∣∣∣
t=0
Applying this formula we obtain the following result:
Theorem 3. If X follows the CMPII distribution, then its nth moment is:
EXn =
n!
can(1− θ)(1− 2θ) · · · (1− nθ) −
n!(1 + θ/b)n−
1
θ
can(1− θ)(1− 2θ) · · · (1− nθ) , (θ <
1
n
).
One can verify that the first and second moments calculated in Theorem 1 agree
with those dictated by Theorem 3.
4.5 Summary
We have described CMPII, a three-parameter survival distribution that we derived
from a cure-mixture frailty model. One can view the CMPII as a variation of the
Pareto family whose density arises as a linear combination of two Pareto II densities.
The CMPII family includes as special cases several known distributions.
In Appendix 4.6, we provide the proofs of the Theorems in Section 4.4. The
easiest way to derive the characteristic function and moments would seem to be
deriving based on the formulas for the Pareto II distribution, similar to what we did
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to derive expectation and variance (Appendix 4.6.1). However, we were unable to
find these formulas for the Pareto II distribution in a literature search, and therefore
we elected to derive them for the CMPII directly (see Appendices 4.6.2 and 4.6.3).
The derivations are complicated but may serve as examples for similar derivations of
other distributions.
Pareto distributions have been known for several decades (Arnold (1983); Arnold
and Laguna (1977)) and have been applied in various areas of science, especially
in economics to describe income distributions and in medical statistics to describe
survival distributions. Naturally this new CMPII distribution can be applied to these
areas as well. Our earlier work (Li et al. (2010)) is one possible use; other potential
applications deserve further investigation.
4.6 Appendix: Proof the Theorems about CMPII
Distribution
4.6.1 Proof of Theorem 1
In this proof, we will use some facts about Pareto II distribution (Johnson et al.
(1994)): If a survival time X follows Pareto II (µ, σ, ξ), then
E(X) =
σ
1− ξ , ξ < 1; (4.6.1)
E(X2) =
2σ2
(1− ξ)(1− 2ξ) , ξ < 1/2. (4.6.2)
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If X follows the CMPII distribution, then its expectation is
E(X) = αE(X1 ∼ f1)− βE(X2 ∼ f2) (by equation (4.2.4))
=
1
c
· 1
a(1− θ) −
(1 + θ/b)−
1
θ
c
· 1 + θ/b
a(1− θ) (by equation (4.6.1))
=
1
ca(1− θ)
(
1− (1 + θ/b)− 1θ+1
)
=
1
a(1− θ) ·
1− (1 + θ/b)− 1θ+1
1− (1 + θ/b)− 1θ , θ < 1. (4.6.3)
Similarly, the second moment of X is
E(X2) = αE(X21 , X1 ∼ f1)− βE(X22 , X2 ∼ f2)
=
1
c
· 2
a2(1− θ)(1− 2θ) −
(1 + θ/b)−
1
θ
c
· 2(1 + θ/b)
2
a2(1− θ)(1− 2θ)
=
2
ca2(1− θ)(1− 2θ)
(
1− (1 + θ/b)− 1θ+2
)
=
2
a2(1− θ)(1− 2θ) ·
1− (1 + θ/b)− 1θ+2
1− (1 + θ/b)− 1θ , θ < 1/2. (4.6.4)
Accordingly, the variance of X is
Var(X) = E(X2)− (E(X))2
=
2
a2(1− θ)(1− 2θ) ·
1− (1 + θ/b)− 1θ+2
1− (1 + θ/b)− 1θ
− 1
a2(1− θ)2 ·
[
1− (1 + θ/b)− 1θ+1
1− (1 + θ/b)− 1θ
]2
, θ < 1/2. (4.6.5)
4.6.2 Proof of Theorem 2
In this proof, we use the fact that∫ ∞
0
(x+ w)ve−uxdx = u−v−1ewuΓ(v + 1, wu); (4.6.6)
where u, v, w are complex numbers with constraints |arg w| < pi, Re u > 0; and
Γ(·, ·) is the upper incomplete Gamma function (Gradshteyn and Ryzhik (1980)).
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Based on equation (4.2.4), we have
φ(t) = E(eitX) = αE(eitX , X ∼ f1)− βE(eitX , X ∼ f2). (4.6.7)
Now
E(eitX , X ∼ f1) = a
∫ ∞
0
eitx(1 + θax)−
1
θ
−1dx
= a(θa)−
1
θ
−1
∫ ∞
0
(
x+
1
θa
)− 1
θ
−1
eitxdx
= a(θa)−
1
θ
−1(−it) 1θ exp
(
− it
θa
)
Γ
(
−1
θ
,− it
θa
)
, use (4.6.6)
=
1
θ
(
− it
θa
) 1
θ
exp
(
− it
θa
)
Γ
(
−1
θ
,− it
θa
)
, (4.6.8)
and
E(eitX , X ∼ f2) = a
1 + θ/b
∫ ∞
0
eitx
(
1 +
θa
1 + θ/b
x
)− 1
θ
−1
dx
=
a
1 + θ/b
(
θa
1 + θ/b
)− 1
θ
−1 ∫ ∞
0
(
x+
1 + θ/b
θa
)− 1
θ
−1
eitxdx
=
a
1 + θ/b
(
θa
1 + θ/b
)− 1
θ
−1
(−it) 1θ
· exp
(
− it(1 + θ/b)
θa
)
Γ
(
−1
θ
,−it(1 + θ/b)
θa
)
, use (4.6.6)
=
1
θ
(
− it
θa
) 1
θ
(1 + θ/b)
1
θ
· exp
(
− it(1 + θ/b)
θa
)
Γ
(
−1
θ
,−it(1 + θ/b)
θa
)
; (4.6.9)
Substituting (4.6.8) and (4.6.9) into (4.6.7) gives
φ(t) =
1
cθ
(
− it
θa
) 1
θ
[
exp
(
− it
θa
)
Γ
(
−1
θ
,− it
θa
)
− exp
(
−it(1 + θ/b)
θa
)
Γ
(
−1
θ
,−it(1 + θ/b)
θa
)]
. (4.6.10)
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4.6.3 Proof of Theorem 3
We first note a series of lemmas.
Lemma 1.
∂n(z−sΓ(s, z))
∂nz
= (−1)nz−s−nΓ(s+ n, z)
Proof. See Gradshteyn and Ryzhik (1980).
Lemma 2.
−z−sΓ(s, z)|z=0 = 1
s
, (s < 0).
Proof.
z−sΓ(s, z) = z−s
∫ ∞
z
ts−1e−tdt =
∫ ∞
1
ys−1ezydy (let y =
t
z
),
−z−sΓ(s, z)|z=0 =
∫ ∞
1
ys−1dy = −1
s
, (s < 0).
Lemma 3. Define g(z, s) = ezz−sΓ(s, z). Then
∂g(z, s)
∂z
= −g(z, s+ 1) + g(z, s);
∂g(z, s)
∂z
∣∣∣∣
z=0
=
−1
s(s+ 1)
, (s < −1).
Proof.
∂g(z, s)
∂z
=
∂(ezz−sΓ(s, z))
∂z
= ez
∂(z−sΓ(s, z))
∂z
+ ez(z−sΓ(s, z))
= ez(−z−s−1Γ(s+ 1, z)) + ez(z−sΓ(s, z)) (by Lemma 1)
= −g(z, s+ 1) + g(z, s);
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∂g(z, s)
∂z
∣∣∣∣
z=0
= −z−s−1Γ(s+ 1, z)|z=0 + z−sΓ(s, z)|z=0
=
1
s+ 1
− 1
s
(by Lemma 2)
=
−1
s(s+ 1)
, (s < −1).
Lemma 4.
∂gn(z, s)
∂zn
=
n∑
k=0
(−1)k
(
n
k
)
g(z, s+ k).
Proof. Denoting An = ∂g
n(z, s)/∂zn, we prove the lemma by induction. Supposing
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it is true for n, then for n+ 1,
An+1 =
∂An
∂z
=
n∑
k=0
(−1)k
(
n
k
)
∂g(z, s+ k)
∂z
=
n∑
k=0
(−1)k
(
n
k
)
[g(z, s+ k)− g(z, s+ k + 1)] (by Lemma 3)
=
n∑
k=0
(−1)k
(
n
k
)
g(z, s+ k) +
n∑
k=0
(−1)k+1
(
n
k
)
g(z, s+ k + 1)
=
n∑
k=0
(−1)k
(
n
k
)
g(z, s+ k) +
n+1∑
l=1
(−1)l
(
n
l − 1
)
g(z, s+ l) (let l = k + 1)
= g(z, s) +
n∑
k=1
(−1)k
(
n
k
)
g(z, s+ k)
+
n∑
l=1
(−1)l
(
n
l − 1
)
g(z, s+ l) + (−1)n+1g(z, s+ n+ 1)
= g(z, s) +
n∑
k=1
(−1)k
(
n
k
)
g(z, s+ k)
+
n∑
l=1
(−1)l
(
n
l
)
l
n− l + 1g(z, s+ l) + (−1)
n+1g(z, s+ n+ 1)
= g(z, s) +
n∑
k=1
(−1)k
(
n
k
)
n+ 1
n− k + 1g(z, s+ k) + (−1)
n+1g(z, s+ n+ 1)
= g(z, s) +
n∑
k=1
(−1)k
(
n+ 1
k
)
g(z, s+ k) + (−1)n+1g(z, s+ n+ 1)
=
n+1∑
k=0
(−1)k
(
n+ 1
k
)
g(z, s+ k),
so it is true for n+ 1 as well.
Lemma 5.
∂gn(z, s)
∂zn
∣∣∣∣
z=0
=
n−1∑
k=0
(−1)k
(
n− 1
k
)
1
(s+ k)(s+ k + 1)
, (s+ n < 0).
72
Proof.
∂gn(z, s)
∂zn
∣∣∣∣
z=0
=
∂
∂z
(
∂gn−1(z, s)
∂zn−1
)
∣∣∣∣
z=0
=
∂
∂z
n−1∑
k=0
(−1)k
(
n− 1
k
)
g(z, s+ k)
∣∣∣∣
z=0
(by Lemma 4)
=
n−1∑
k=0
(−1)k
(
n− 1
k
)
∂g(z, s+ k)
∂z
∣∣∣∣
z=0
=
n−1∑
k=0
(−1)k
(
n− 1
k
) −1
(s+ k)(s+ k + 1)
(by Lemma 3).
Lemma 6.
∂gn(z, s)
∂zn
∣∣∣∣
z=0
=
−n!
s(s+ 1) · · · (s+ n) , (s+ n < 0).
Proof. Setting Bn(s) = ∂g
n(z, s)/∂zn|z=0, we again prove the lemma using induction.
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If it is true for n, then for n+ 1,
Bn+1(s) =
n∑
k=0
(−1)k
(
n
k
)
1
(s+ k)(s+ k + 1)
(by Lemma 5)
=
1
s(s+ 1)
+
n−1∑
k=1
(−1)k
(
n
k
)
1
(s+ k)(s+ k + 1)
+ (−1)n 1
(s+ n)(s+ n+ 1)
=
1
s(s+ 1)
+
n−1∑
k=1
(−1)k
[(
n− 1
k
)
+
(
n− 1
k
)
k
n− k
]
1
(s+ k)(s+ k + 1)
+(−1)n 1
(s+ n)(s+ n+ 1)
=
1
s(s+ 1)
+
n−1∑
k=1
(−1)k
(
n− 1
k
)
1
(s+ k)(s+ k + 1)
+
n−1∑
k=1
(−1)k
(
n− 1
k
)
k
n− k
1
(s+ k)(s+ k + 1)
+ (−1)n 1
(s+ n)(s+ n+ 1)
= Bn(s) +
n−1∑
k=1
(−1)k
(
n− 1
k − 1
)
1
(s+ k)(s+ k + 1)
+ (−1)n 1
(s+ n)(s+ n+ 1)
= Bn(s)−
n−2∑
l=0
(−1)l
(
n− 1
l
)
1
(s+ l + 1)(s+ l + 2)
+ (−1)n 1
(s+ n)(s+ n+ 1)
(let l = k − 1)
= Bn(s)−
n−1∑
l=0
(−1)l
(
n− 1
l
)
1
(s+ l + 1)(s+ l + 2)
+(−1)n−1 1
(s+ n)(s+ n+ 1)
+ (−1)n 1
(s+ n)(s+ n+ 1)
= Bn(s)−
n−1∑
l=0
(−1)l
(
n− 1
l
)
1
(s+ l + 1)(s+ l + 2)
= Bn(s)−Bn(s+ 1)
=
−n!
s(s+ 1) · · · (s+ n) −
−n!
(s+ 1)(s+ 2) · · · (s+ n+ 1) (because it is true for n)
=
−(n+ 1)!
s(s+ 1) · · · (s+ n+ 1) ,
so it is true for n+ 1 as well.
Based on these lemmas we can prove Theorem 3 easily. Denote z1 = −(it)/(θa),
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z2 = −[it(1 + θ/b)]/(θa) and s = −1/θ, then
φ(t) =
α
θ
z−s1 e
z1Γ(s, z1)− β
θ
z−s2 e
z2Γ(s, z2) =
α
θ
g(z1, s)− β
θ
g(z2, s),
∂φn
∂tn
∣∣∣∣
t=0
=
α
θ
∂gn(z1, s)
∂zn1
∣∣∣∣
z1=0
(
∂z1
∂t
)n
− β
θ
∂gn(z2, s)
∂zn2
∣∣∣∣
z2=0
(
∂z2
∂t
)n
=
α
θ
−n!
s(s+ 1) · · · (s+ n)
(−i
θa
)n
−β
θ
−n!
s(s+ 1) · · · (s+ n)
(−i(1 + θ/b)
θa
)n
(by Lemma 6)
= α
in
an
n!
(1− θ)(1− 2θ) · · · (1− nθ) − β
in
an
(1 + θ/b)n
n!
(1− θ)(1− 2θ) · · · (1− nθ) ,
EXn = i−n
∂φn
∂tn
∣∣∣∣
t=0
= α
1
an
n!
(1− θ)(1− 2θ) · · · (1− nθ) − β
1
an
(1 + θ/b)n
n!
(1− θ)(1− 2θ) · · · (1− nθ)
=
n!
can(1− θ)(1− 2θ) · · · (1− nθ) −
n!(1 + θ/b)n−
1
θ
can(1− θ)(1− 2θ) · · · (1− nθ) , (θ <
1
n
).
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Figure 4.1: Log density and hazard function when b = 1.
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Figure 4.2: Log density and hazard function when a = 1 and θ = 1.
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Figure 4.3: Log density function when b → 0.
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Figure 4.5: Relationship of CMPII distribution and other distributions.
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Chapter 5
Conclusion
We have proposed a multivariate cure-mixture frailty model to describe the re-
current time-to-event data with alternating states and a possibility of cure, as the
data from smoking cessation clinical trials. And based on it, we further developed a
Bayesian method to predict individuals’ long-term smoking behaviors from the short-
term observed data.
Our model is superior to the traditional approach in several aspects. First, it
makes efficient use of the behavioral information in the raw daily records. By ana-
lyzing the length of abstinent and smoking events, our model describes the complete
process of transition between smoking states, not merely the length of the first at-
tempt or smoking behavior in the neighborhood of EOT. Second, it provide more
insights about the drug action than simply answering the question whether the drug
is effective for assisting smoking cessation. By incorporating a cure probability, our
model allows one to describe drug effects on both the daily hazard and the long-term
cure probability; clinically the drug would be of greater interest if it could increase
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the underlying cure probability besides temporarily delay the transition into a lapse.
And by analyzing two types of events jointly, one could examine whether the drug is
effective at inhibiting lapses, promoting recoveries, or both, and thus have a better
understanding about the mechanism of the drug action.
Our model describes transition times between smoking and quitting, and an al-
ternative way of representing the data is to model the binary daily smoking status.
As subjects have repeated measurements over 56 days, one could construct a mixed-
effects logistic regression with a random intercept at subject level. To reflect the
potential dependence of the current smoking status on the history, one could intro-
duce a time series correlation structure among the outcomes, or simply include the
previous smoking status, or some summaries of the history data as predictors. And
similar to what have done in Chapter 3, such binary models could also be utilized for
prediction. Ideally by exploring all possible predictors, we wish to find a set of them
that can completely explain the probability of smoking without the need of a random
effect, so that one can predict the next outcome by evaluating the history data only.
Another variation of the current model would be to describe the daily cigarette
consumption directly, rather than the lengths of abstinence and smoking events. This
would answer a slightly different but equally important question: whether the drug
would help reduce the intensity of the smoking rate. Similar to the idea of cure
model with survival analysis, a count regression for such data needs to accommodate
a possibility of true abstinence, reflected by excess zeros observed in the daily cigarette
counts within a subject. Such methods are known as zero-inflated Poisson or negative
binomial regression (Lambert (1992)). Moreover, as the cigarette counts are self-
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reported and thus subject to “heaping” (Wang and Heitjan (2008)), the model may
also need to incorporate the potential rounding errors.
Nevertheless, the methodologies presented in this dissertation provide a valuable
tool for understanding the drug effects and individual behavior patterns in smoking
cessation clinical trials. And although tailored for the smoking cessation data, the
methods are potentially applicable in other studies that involve recurrent events and
possibilities of cure.
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